Clinical trial
Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (Sinopharm BBIBP-CorV) Coadministered With Rabies Vaccine in China: a Multicentre, Randomised, Controlled, Phase 4 Trial
NCT05453487 is registered in ClinicalTrials.gov with China National Biotec Group Company Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (Sinopharm BBIBP-CorV) Coadministered With Rabies Vaccine in China: a Multicentre, Randomised, Controlled, Phase 4 Trial
- Lead sponsor
- China National Biotec Group Company Limited
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- July 21, 2022
- Completion date
- June 30, 2023
- Enrollment
- 360 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.